Q1 Earnings Estimate for AXSM Issued By Leerink Partnrs

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Axsome Therapeutics in a research note issued on Monday, February 10th. Leerink Partnrs analyst M. Goodman anticipates that the company will earn ($1.48) per share for the quarter. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.70) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($0.65) EPS, FY2027 earnings at $3.85 EPS and FY2028 earnings at $9.90 EPS.

AXSM has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $190.00 price objective on shares of Axsome Therapeutics in a research note on Tuesday. StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Robert W. Baird lifted their price target on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Leerink Partners upped their price objective on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Bank of America lifted their target price on Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a research note on Tuesday. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $147.13.

Axsome Therapeutics Stock Up 4.0 %

NASDAQ:AXSM opened at $132.20 on Wednesday. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The firm has a market cap of $6.41 billion, a PE ratio of -20.25 and a beta of 1.05. The company has a 50-day moving average of $95.28 and a 200 day moving average of $92.07. Axsome Therapeutics has a 1-year low of $64.11 and a 1-year high of $134.19.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.38) by $0.04. The firm had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same quarter last year, the firm posted ($1.32) earnings per share.

Hedge Funds Weigh In On Axsome Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of AXSM. Creative Planning grew its position in Axsome Therapeutics by 29.8% during the 3rd quarter. Creative Planning now owns 10,854 shares of the company’s stock worth $975,000 after purchasing an additional 2,489 shares during the last quarter. Values First Advisors Inc. purchased a new stake in shares of Axsome Therapeutics during the third quarter valued at $568,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Axsome Therapeutics by 22.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after acquiring an additional 318 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in Axsome Therapeutics by 4.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 19,808 shares of the company’s stock worth $1,780,000 after acquiring an additional 754 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Axsome Therapeutics by 65.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,232 shares of the company’s stock worth $830,000 after acquiring an additional 3,652 shares during the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.